Related Experiment Video
Updated: Jun 5, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Intratumoral immune cell manipulations as a strategy to enhance cancer vaccine efficiency
James Adeosun1, Mohammad Omar Faruk Shaikh2, Timothy Brauns2
1Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; University of Cambridge, School of Clinical Medicine, Cambridge, UK.
Abstract:
Shortcomings in cancer vaccine development are attributable to weak and transient anti-tumor cellular responses in the tumor microenvironment. This restriction of efficacy may be due to an intratumoral immunosuppressive milieu, consisting of regulatory T cells, M2 macrophages, and myeloid derived suppressor cells. Here, we analyze recent advances and propose future directions in the modulation of cellular state propensities combined with cancer vaccines.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
The Tumor Microenvironment
Targeted Cancer Therapies
There are several types of targeted therapies against...

